Cell penetration properties of a highly efficient mini maurocalcine peptide

Pharmaceuticals

Volumn 6, Issue 3, 2013, Pages 320-339

  Tisseyre, Céline ^a,b,c   Bahembera, Eloi ^a,b,c   Dardevet, Lucie ^a,b,c   Sabatier, Jean Marc ^d   Ronjat, Michel ^a,b,c   De Waard, Michel ^a,b,c,e  

^a GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^b Laboratory of Excellence Ion Channel Science and Therapeutics   (France)

^c UNIV GRENOBLE ALPES   (France)

^d INSERM   (France)

^e Biopolis   (France)

Author keywords

Analogs; Cell penetrating peptide; F98 cells; Glioma; Hadrucalcin; Maurocalcine; Toxin

Indexed keywords

CELL PENETRATING PEPTIDE; HISTIDINE; MAUROCALCINE; PENETRATIN; POLYARGININE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACIDITY; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL; CELL MEMBRANE PERMEABILITY; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOCYTOSIS; GLIOMA; HYDROPHOBICITY; INTERNALIZATION; NONHUMAN; PH MEASUREMENT; POINT MUTATION; PROTON TRANSPORT; RAT; SITE DIRECTED MUTAGENESIS; SUBSTITUTION REACTION;

EID: 84875331289     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6030320     Document Type: Article

References (35)

1. Fajloun, Z.; Kharrat, R.; Chen, L.; Lecomte, C.; di Luccio, E.; Bichet, D.; El Ayeb, M.; Rochat, H.; Allen, P.D.; Pessah, I.N.; et al. Chemical synthesis and characterization of maurocalcine, a scorpion toxin that activates Ca2+ release channel/ryanodine receptors. FEBS Lett. 2000, 469, 179-185.
2. Mouhat, S.; Jouirou, B.; Mosbah, A.; de Waard, M.; Sabatier, J.M. Diversity of folds in animal toxins acting on ion channels. Biochem J. 2004, 378, 717-726.
3. Mosbah, A.; Kharrat, R.; Fajloun, Z.; Renisio, J.G.; Blanc, E.; Sabatier, J.M.; El Ayeb, M.; Darbon, H. A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Proteins 2000, 40, 436-442.
4. Zamudio, F.Z.; Gurrola, G.B.; Arevalo, C.; Sreekumar, R.; Walker, J.W.; Valdivia, H.H.; Possani, L.D. Primary structure and synthesis of imperatoxin A (iptx(a)), a peptide activator of Ca2+ release channels/ryanodine receptors. FEBS Lett. 1997, 405, 385-389.
5. Zhu, S.; Darbon, H.; Dyason, K.; Verdonck, F.; Tytgat, J. Evolutionary origin of inhibitor cystine knot peptides. FASEB J. 2003, 17, 1765-1767.
6. Shahbazzadeh, D.; Srairi-Abid, N.; Feng, W.; Ram, N.; Borchani, L.; Ronjat, M.; Akbari, A.; Pessah, I.N.; de Waard, M.; El Ayeb, M. Hemicalcin, a new toxin from the iranian scorpion hemiscorpius lepturus which is active on ryanodine-sensitive Ca2+ channels. Biochem. J. 2007, 404, 89-96.
7. Schwartz, E.F.; Capes, E.M.; Diego-Garcia, E.; Zamudio, F.Z.; Fuentes, O.; Possani, L.D.; Valdivia, H.H. Characterization of hadrucalcin, a peptide from hadrurus gertschi scorpion venom with pharmacological activity on ryanodine receptors. Br. J. Pharmacol. 2009, 157, 392-403.
8. Altafaj, X.; France, J.; Almassy, J.; Jona, I.; Rossi, D.; Sorrentino, V.; Mabrouk, K.; de Waard, M.; Ronjat, M. Maurocalcine interacts with the cardiac ryanodine receptor without inducing channel modification. Biochem. J. 2007, 406, 309-315.
9. Szappanos, H.; Smida-Rezgui, S.; Cseri, J.; Simut, C.; Sabatier, J.M.; de Waard, M.; Kovacs, L.; Csernoch, L.; Ronjat, M. Differential effects of maurocalcine on Ca2+ release events and depolarization-induced Ca2+ release in rat skeletal muscle. J. Physiol. 2005, 565, 843-853.
10. Gurrola, G.B.; Arevalo, C.; Sreekumar, R.; Lokuta, A.J.; Walker, J.W.; Valdivia, H.H. Activation of ryanodine receptors by imperatoxin A and a peptide segment of the II-III loop of the dihydropyridine receptor. J. Biol. Chem. 1999, 274, 7879-7886.
11. Esteve, E.; Mabrouk, K.; Dupuis, A.; Smida-Rezgui, S.; Altafaj, X.; Grunwald, D.; Platel, J.C.; Andreotti, N.; Marty, I.; Sabatier, J.M.; et al. Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. J. Biol. Chem. 2005, 280, 12833-12839.
12. Tanabe, T.; Beam, K.G.; Adams, B.A.; Niidome, T.; Numa, S. Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature 1990, 346, 567-569.
13. Tanabe, T.; Beam, K.G.; Powell, J.A.; Numa, S. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. Nature 1988, 336, 134-139.
14. Altafaj, X.; Cheng, W.; Esteve, E.; Urbani, J.; Grunwald, D.; Sabatier, J.M.; Coronado, R.; de Waard, M.; Ronjat, M. Maurocalcine and domain a of the II-III loop of the dihydropyridine receptor Cav1.1 subunit share common binding sites on the skeletal ryanodine receptor. J. Biol. Chem. 2005, 280, 4013-4016.
15. Chen, L.; Esteve, E.; Sabatier, J.M.; Ronjat, M.; de Waard, M.; Allen, P.D.; Pessah, I.N. Maurocalcine and peptide a stabilize distinct subconductance states of ryanodine receptor type 1, revealing a proportional gating mechanism. J. Biol. Chem. 2003, 278, 16095-16106.
16. Poillot, C.; Dridi, K.; Bichraoui, H.; Pecher, J.; Alphonse, S.; Douzi, B.; Ronjat, M.; Darbon, H.; de Waard, M. D-maurocalcine, a pharmacologically inert efficient cell-penetrating peptide analogue. J. Biol. Chem. 2010, 285, 34168-34180.
17. Mabrouk, K.; Ram, N.; Boisseau, S.; Strappazzon, F.; Rehaim, A.; Sadoul, R.; Darbon, H.; Ronjat, M.; de Waard, M. Critical amino acid residues of maurocalcine involved in pharmacology, lipid interaction and cell penetration. Biochim. Biophys. Acta 2007, 1768, 2528-2540.
18. Ram, N.; Weiss, N.; Texier-Nogues, I.; Aroui, S.; Andreotti, N.; Pirollet, F.; Ronjat, M.; Sabatier, J.M.; Darbon, H.; Jacquemond, V.; et al. Design of a disulfide-less, pharmacologically-inert and chemically-competent analog of maurocalcine for the efficient transport of impermeant compounds into cells. J. Biol. Chem. 2008, 283, 27048-27056.
19. Poillot, C.; Bichraoui, H.; Tisseyre, C.; Bahemberae, E.; Andreotti, N.; Sabatier, J.M.; Ronjat, M.; de Waard, M. Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine. J. Biol. Chem. 2012, 287, 17331-17342.
20. Aroui, S.; Brahim, S.; de Waard, M.; Breard, J.; Kenani, A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. Cancer Lett. 2009, 285, 28-38.
21. Aroui, S.; Brahim, S.; de Waard, M.; Kenani, A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochem. Biophys. Res. Commun. 2010, 391, 419-425.
22. Aroui, S.; Brahim, S.; Hamelin, J.; de Waard, M.; Breard, J.; Kenani, A. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous trail-induced apoptosis. Apoptosis 2009, 14, 1352-1365.
23. Aroui, S.; Ram, N.; Appaix, F.; Ronjat, M.; Kenani, A.; Pirollet, F.; de Waard, M. Maurocalcine as a non-toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231. Pharm. Res. 2009, 26, 836-845.
24. Ram, N.; Texier-Nogues, I.; Pernet-Gallay, K.; Poillot, C.; Ronjat, M.; Andrieux, A.; Arnoult, C.; Daou, J.; de Waard, M. In vitro and in vivo cell delivery of quantum dots by the cell penetrating peptide maurocalcine. Int. J. Biomed. Nanosci. Nanotechnol. 2011, 2, 12-32.
25. Stasiuk, G.J.; Tamang, S.; Imbert, D.; Poillot, C.; Giardiello, M.; Tisseyre, C.; Barbider, E.L.; Fries, P.H.; de Waard, M.; Reiss, P.; Mazzanti, M. Cell-permeable ln(III) chelate-functionalized InP quantum dots as multimodal imaging agents. ACS Nano 2011, 5, 8193-8201.
26. Ram, N.; Aroui, S.; Jaumain, E.; Bichraoui, H.; Mabrouk, K.; Ronjat, M.; Lortat-Jacob, H.; de Waard, M. Direct peptide interaction with surface glycosaminoglycans contributes to the cell penetration of maurocalcine. J. Biol. Chem. 2008, 283, 24274-24284.
27. Boisseau, S.; Mabrouk, K.; Ram, N.; Garmy, N.; Collin, V.; Tadmouri, A.; Mikati, M.; Sabatier, J.M.; Ronjat, M.; Fantini, J.; et al. Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochim. Biophys. Acta 2006, 1758, 308-319.
28. Jones, A.T.; Sayers, E.J. Cell entry of cell penetrating peptides: Tales of tails wagging dogs. J. Control. Release 2012, 161, 582-591.
29. Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U. Cell-penetrating peptides. Trends Pharmacol. Sci. 2000, 21, 99-103.
30. Lundberg, P.; Langel, U. A brief introduction to cell-penetrating peptides. J. Mol. Recognit. 2003, 16, 227-233.
31. Mano, M.; Teodosio, C.; Paiva, A.; Simoes, S.; Pedroso de Lima, M.C. On the mechanisms of the internalization of s4(13)-pv cell-penetrating peptide. Biochem. J. 2005, 390, 603-612.
32. Gurrola, G.B.; Capes, E.M.; Zamudio, F.Z.; Possani, L.D.; Valdivia, H.H. Imperatoxin A, a cell-penetrating peptide from scorpion venom, as a probe of Ca-release channels/ryanodine receptors. Pharmaceuticals (Basel) 2010, 3, 1093-1107.
33. El-Hayek, R.; Lokuta, A.J.; Arevalo, C.; Valdivia, H.H. Peptide probe of ryanodine receptor function. Imperatoxin A, a peptide from the venom of the scorpion pandinus imperator, selectively activates skeletal-type ryanodine receptor isoforms. J. Biol. Chem. 1995, 270, 28696-28704.
34. Garcia-Martin, M.L.; Herigault, G.; Remy, C.; Farion, R.; Ballesteros, P.; Coles, J.A.; Cerdan, S.; Ziegler, A. Mapping extracellular pH in rat brain gliomas in vivo by 1H magnetic resonance spectroscopic imaging: Comparison with maps of metabolites. Cancer Res. 2001, 61, 6524-6531.
35. Merrifield, R.B. Solid-phase peptide synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 1969, 32, 221-296.